CELCUITY INC (CELC)
NASDAQ • Healthcare
Last close at August 11, 2026 at 20:00 UTC
Fundamentals Charts
About CELCUITY INC
Celcuity Inc. is a NASDAQ-listed healthcare company in biotechnology that discovers new cancer sub-types and commercializes diagnostic tests for patients treated with targeted therapies. Founded in 2012, Celcuity operates as an early-stage oncology diagnostics business from Minneapolis, Minnesota, focused on precision cancer classification and testing.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
CELCUITY INC's Technical Indicators Summary
CELC shows a modestly bearish technical picture driven by price sitting just under short-term averages and below intraday VWAP, while most medium- and long-term moving averages remain overhead. Momentum indicators are mixed — a positive short-term momentum reading contrasts with neutral RSI and MACD, and ADX near the mid-teens suggests limited trend strength. Volatility is elevated with an ATR around 5.2, and volume metrics show some accumulation but have not decisively changed the bias. Technical takeaway: Sell.
| Indicator | Value |
|---|---|
RSI (14) | 45.76 |
Stochastic %K (14, 3, 3) | 65.69 |
CCI (20) | 25.31 |
WPR (14) | -33.56 |
Momentum (10) | 6.38 |
MFI | 43.79 |
MACD Level (12, 26) | -2.14 |
Bollinger Bands | $81.26 - $95.45 |
ATR (14) | $5.17 (5.77%) |
ADX (14) | 17.06 |
OBV | 3,200,321 |
VWAP | $89.71 |
Classic Pivot Point | $89.31 |
Fibonacci Pivot Point | $89.31 |
Simple Moving Averages | $88.36 - $108.63(5 indicators) |
Exponential Moving Averages | $90.00 - $101.28(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
A subtle upside move of 1.81% lifts CELC above yesterday's close (88.11). Order flow is faint; current turnover measures just 0.29× the standard run rate. Earnings land in 1 day on 13 August, setting up a pre-release period for CELC.
Trading Volume
Below 10d avg (675.8K)
195.2K
vs S&P 500 Today
Outperforming Market
+1.56%
52-Week Position
Mid-range
42.5%
Updated: August 12, 2026 at 16:41 UTC
Quote Summary
CELC Headlines
FDA clears Celcuity’s Revtorpyk for breast cancer
July 14, 2026
Valuation Gaps Emerge Across Key Mid‑Cap Stocks
February 16, 2026